Inhibitors of the lipoxygenase arachidonic acid pathway impair glycocholate efflux in isolated rat hepatocytes

1991 ◽  
Vol 12 (3) ◽  
pp. 302-311 ◽  
Author(s):  
Jorge Quiroga ◽  
JoséL. Rodríguez-Sanromán ◽  
Francisco Guarner ◽  
Carlos Rodríguez Ortigosa ◽  
JoséM. Aréjola ◽  
...  
1999 ◽  
Vol 57 (11) ◽  
pp. 1311-1319 ◽  
Author(s):  
Susan H Kenyon ◽  
Catherine J Waterfield ◽  
Daniel S Asker ◽  
Mariko Kudo ◽  
David W Moss ◽  
...  

Author(s):  
Masaru Chihara ◽  
Takahide Nomura ◽  
Masakatsu Tachibana ◽  
Hiroko Nomura ◽  
Yukihiko Nomura ◽  
...  

1989 ◽  
Vol 37 (1) ◽  
pp. 23-31 ◽  
Author(s):  
M. Marinovich ◽  
L.M. Flaminio ◽  
M. Papagni ◽  
C.L. Galli

1996 ◽  
Vol 46 (4) ◽  
pp. 311-318 ◽  
Author(s):  
Hideki SAKAI ◽  
Bunpei KAKINOKI ◽  
Martin DIENER ◽  
Noriaki TAKEGUCHI

1990 ◽  
Vol 64 (03) ◽  
pp. 473-477 ◽  
Author(s):  
Shih-Luen Chen ◽  
Wu-Chang Yang ◽  
Tung-Po Huang ◽  
Shiang Wann ◽  
Che-ming Teng

SummaryTherapeutic preparations of desmopressin for parenteral use contain the preservative chlorobutanol (5 mg/ml). We show here that chlorobutanol is a potent inhibitor of platelet aggregation and release. It exhibited a significant inhibitory activity toward several aggregation inducers in a concentration- and time-dependent manner. Thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin respectively were markedly inhibited by chlorobutanol. Chlorobutanol had no effect on elastase- treated platelets and its antiplatelet effect could be reversed. It is concluded that the antiplatelet effect of chlorobutanol is mainly due to its inhibition on the arachidonic acid pathway but it is unlikely to have a nonspecitic toxic effect. This antiplatelet effect of chlorobutanol suggests that desmopressin, when administered for improving hemostasis, should not contain chlorobutanol as a preservative.


Sign in / Sign up

Export Citation Format

Share Document